<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27602363</article-id><article-id pub-id-type="pmc">5012023</article-id><article-id pub-id-type="publisher-id">20020053</article-id><article-id pub-id-type="doi">10.4103/2321-3868.130184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Current status of vascularized composite tissue allotransplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Edtinger</surname><given-names>Karoline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xiaoyong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uehara</surname><given-names>Hanae</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tullius</surname><given-names>Stefan G.</given-names></name><address><email>stullius@partners.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Division of Transplant Surgery and Laboratory of Transplant Surgery Research, Brigham and Women&#x02019;s Hospital and Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115 USA </aff><aff id="Aff2"><label>2</label>Department of Surgery, University Hospital Regensburg, University of Regensburg, Regensburg, Germany </aff><aff id="Aff3"><label>3</label>Division of Urology, Bejing Chao-Yang Hospital, Capital Medical University, Bejing, China </aff><aff id="Aff4"><label>4</label>Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Osaka, Japan </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>2</volume><issue>2</issue><fpage>53</fpage><lpage>60</lpage><history><date date-type="received"><day>6</day><month>3</month><year>2014</year></date><date date-type="rev-recd"><day>9</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Author 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made</license-p></license></permissions><abstract id="Abs1"><p>Vascularized composite tissue allotransplantation (VCA) offers treatment options of complex functional deficiencies that cannot be repaired with conventional reconstructive methods. VCAs consist of blocks of functional units comprising different tissue types such as skin, bone, muscle, nerves, blood vessels, tendons, ligaments and others, and are thus substantially different from the composition of organ transplants. The field of VCA has made fascinating progresses in the recent past. Among other VCAs, numerous successful hand, face and limb transplants have been performed in the world. At the same time, specific questions in regard to innate and adaptive immunity, consequences of ischemia/reperfusion injury, immunosuppression, preservation, and regenerative capacity remain. In spite of this, the field is poised to make significant advances in the near future.</p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Face transplantation</kwd><kwd>hand transplantation</kwd><kwd>immunosuppression</kwd><kwd>composite tissue transplantation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Vascularized composite tissue allotransplantation (VCA) &#x02014; recent developments leading to a clinical reality</title><p>Organ and tissue transplants including the replacement of limbs have been a long-standing dream.[<xref ref-type="bibr" rid="CR1">1</xref>] At the same time, rapid advances in solid organ transplantation (SOT) paved the way for the current success of VCAs.</p><p>World War II initiated a more in-depth exploration of skin transplants for the treatment of burned warriors. These efforts had subsequently inspired a team in Boston led by Joseph E. Murray to perform the first successful SOT between identical twins.[<xref ref-type="bibr" rid="CR2">2</xref>] The same team went on in the following years to establish successful renal transplants between nonidentical living donors, followed shortly thereafter by the first renal transplant from a deceased donor with chemical immunosuppression.[<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>]<table-wrap id="TabA"><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Access this article online</th></tr></thead><tbody><tr><td rowspan="2">
<bold>Quick Response Code</bold>: <inline-graphic xlink:href="41038_2014_20020053_Figa.gif" id="d30e266"/>
</td><td>
<bold>Website</bold>: <ext-link ext-link-type="uri" xlink:href="http://www.burnstrauma.com">www.burnstrauma.com</ext-link>
</td></tr><tr><td>
<bold>DOI</bold>: 10.4103/2321-3868.130184</td></tr></tbody></table></table-wrap></p><p>The first successful human VCA, an en block digital flexor tendon, was conducted by Erle E. Peacock Jr. in North Carolina in the absence of immunosuppression in 1957 and coined the term composite tissue allotransplantation (CTA).[<xref ref-type="bibr" rid="CR5">5</xref>] A first hand transplant, although clinically not successful, was performed in 1964 with chemical immunosuppression in Ecuador by Robert Gilbert.[<xref ref-type="bibr" rid="CR6">6</xref>] A long period of stagnation in VCA followed, mainly based on the paradigm that the potent antigenicity of the skin could not be sufficiently managed by immunosuppressants.[<xref ref-type="bibr" rid="CR71">71</xref>] In the meantime, immunosuppression became more refined for SOT.[<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>] Addressing the paradigm of intensified antigenicity in VCAs, interesting experimental work in the early 1990s demonstrated that the transplantation of a whole limb was linked to a less intense immune response as compared to individual components such as the skin.[<xref ref-type="bibr" rid="CR10">10</xref>] First successful limb transplantations in pigs, treated with a triple immunosuppressive therapy consisting of cyclosporin (CsA), mycophenolate mofetil (MMF), and prednisone encouraged a team led by Jean-Michel Dubernard in France to conduct the first successful hand transplantation in 1998.[<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref>] Additional hand transplants were performed rapidly thereafter in the USA and China, while other successful composite tissue transplants such as larynx and knee transplants were subsequently reported.[<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>] First successful face transplants were performed in 2005 in France and thereafter in China and the US (Cleveland and Boston). In 2013, the transplantation of bilateral transfemoral lower extremities was reported[<xref ref-type="bibr" rid="CR15">15</xref>] [Figure <xref rid="Fig1" ref-type="fig">1</xref>]. Most recently, an important regulatory issue has been resolved and VCAs are now officially covered by United Network for Organ Sharing (UNOS) guidelines since 2013 in the USA, which ended a long-lasting discussion whether allocation of VCAs should fall under the regulatory framework of tissue or organ transplants.[<xref ref-type="bibr" rid="CR28">28</xref>]<fig id="Fig1"><label>Figure 1:</label><caption><p>Progress in clinical vascularized composite tissue allotransplantation (VCA): Year of transplantation or publication.[<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]</p></caption><graphic xlink:href="41038_2014_20020053_Fig1" id="d30e349"/></fig></p><p>Although major unsolved issues including the need for a more refined immunosuppression and missing long-term results remain, the last decade has seen major advances in VCA [Table <xref rid="Tab1" ref-type="table">1</xref>].<table-wrap id="Tab1"><label>Table 1:</label><caption><p>
<bold>Current success and challenges in VCA</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Achievements</th><th>Challenges</th></tr></thead><tbody><tr><td>Excellent esthetic and functional outcome</td><td>Minimization of immunosuppression, tolerance induction</td></tr><tr><td>Multidisciplinary approach</td><td>Protocols for sensitized patients</td></tr><tr><td>Recognition as organ, regulated by OPTN</td><td>Improved monitoring</td></tr><tr><td>Excellent patient and graft survival</td><td>Mechanisms of rejection Acute cellular and humoral rejection</td></tr><tr><td/><td>Acute cellular and humoral rejection</td></tr><tr><td/><td>Chronic graft deterioration</td></tr><tr><td/><td>Nerve regeneration</td></tr><tr><td/><td>Definition of acceptable ischemic times</td></tr><tr><td/><td>Refined organ preservation</td></tr></tbody></table><table-wrap-foot><p>VCA = Vascularized composite tissue allotransplantation, OPTN = Organ Procurement and Transplantation Network</p></table-wrap-foot></table-wrap></p><sec id="Sec2"><title>Immunosuppression and immune modulation in VCA</title><p>The immunosuppressive regimen in VCA continues to evolve in parallel with SOT. Indeed, the refinement of long-term immunosuppression seems of particular importance for the &#x02018;life-giving&#x02019; rather than &#x02018;life-saving&#x02019; VCA approach. At the same time, VCAs offer opportunities for immunomodulation such as the transplantation of bony structures (including bone marrow (BM)) with potential relevance of tolerance enabling protocols and the application of topical treatment.</p></sec><sec id="Sec3"><title>Face transplantation</title><p>In face transplantation, most patients received an induction treatment with anti-thymocyte globulin (e.g., thymoglobulin) in varying doses of 1&#x02013;2 mg/kg/day[<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR29">29</xref>] for up to 10 days[<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref>] after transplantation. Some teams decided on an induction treatment with an anti-interleukin-2 receptor (anti-IL-2R) antibody (e.g., basiliximab).[<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>] Steroids were administered in 500&#x02013;1,000 mg intravenous (i.v.) boluses of methylprednisolone,[<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref>] or, alternatively 250&#x02013;500 mg prednisone[<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR35">35</xref>] on the day of transplantation, then tapered to daily prednisone doses of 5&#x02013;20 mg/day. In the VCA program at Brigham and Women&#x02019;s Hospital in Boston, we were able to wean all our nonsensitized recipients off steroids.[<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR36">36</xref>]</p><p>Maintenance therapy is usually initiated on day 1 with calcineurin inhibitors (CNIs), in general tacrolimus, in all reported face transplantations with doses adjusted to maintain through levels of 10&#x02013;15 ng/ml during the first 1&#x02013;3 months in majority of cases and subsequent tapering to levels as low as 3&#x02013;5 ng/ml.[<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR37">37</xref>] Moreover, MMF was part of the standard triple immunosuppression regimen in face transplantation and was uniformly prescribed at dosages of 2 g/day early after transplantation and tapered thereafter.[<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR33">33</xref>] Some teams have tested the feasibility of CNI free protocols. A progressive decline in renal function or malignancies have prompted some to switch to CNI free maintenance immunosuppression based on sirolimus treatment with a targeted trough level of 8&#x02013;12 ng/ml.[<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref>]</p><p>Early acute rejections (grade I and II) have usually been treated with increasing dosages of maintenance immunosuppression, in some cases, topical treatment with tacrolimus and clobetazol ointments, and prednisone mouthwashes.[<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR35">35</xref>] In the absence of adequate response or in more advanced rejections (grade III), steroid pulses have been necessary. A few cases required an escalation to anti-thymocyte globulin therapy plus a modification in the maintenance immunosuppression protocol.[<xref ref-type="bibr" rid="CR6">6</xref>]</p><p>Of note, not all low grade acute rejections have required treatment and most centers have been assessing both histology and clinical presentation.[<xref ref-type="bibr" rid="CR34">34</xref>] It remains unclear at this point, if low grade rejections are self-limiting or if the currently applied pathological scores necessarily distinguish rejection from unspecific-inflammatory events. Extracorporeal photochemotherapy (ECPCT) has been introduced in a few patients. This immunomodulatory approach demonstrated a complementary effect on preventing rejections in the absence of the known side effects of conventional immunosuppression. Although the mode of action of ECPCT is not completely clear, ECPCT has been used successfully both long-term in patients with ongoing low grade rejections and in patients with simultaneous rejections and infections.[<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR39">39</xref>]</p></sec><sec id="Sec4"><title>Hand transplantation</title><p>Immunosuppression in hand transplantation parallels largely to regimens in other VCA approaches including face transplantation. At the same time, the experience is larger and &#x02018;stakes&#x02019; may be slightly lower, thus allowing pushing the envelope in this area. Most teams around the world have utilized a triple immunosuppression with tacrolimus, MMF and methylprednisolone, and an induction treatment with either a polyclonal antithymocyte globulin or a monoclonal anti-IL-2R.[<xref ref-type="bibr" rid="CR12">12</xref>] More recently, alemtuzumab (an anti-CD52 antibody) has been utilized by some centers as an induction agent.[<xref ref-type="bibr" rid="CR40">40</xref>] Along the same line as with the experience in face transplantation, CNI-based protocols have been switched to sirolimus subsequently due to side-effects such as unstable glucose blood levels.[<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref>]</p></sec><sec id="Sec5"><title>Clinical and pathological diagnosis of acute rejection in VCA</title><p>VCAs typically consist of various tissues originating from different embryological germ layers.[<xref ref-type="bibr" rid="CR43">43</xref>] It is assumed that the skin is most sensitive to rejection, while vessels, muscles, and especially nerves are afflicted to a lesser degree.[<xref ref-type="bibr" rid="CR44">44</xref>] Local or scattered erythema is usually considered as a clinical sign of an early acute rejection. Moderate acute rejections present with pink erythematous macules, more advanced acute rejections with scaly papules or plaques, and the irreversible grade IV state with necrosis and/or ulceration of the graft.[<xref ref-type="bibr" rid="CR44">44</xref>]</p><p>Scoring systems based on histopathological findings classifying acute rejections of VCAs have been proposed by several groups.[<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>] In 2007, an international team of surgeons, pathologists, and basic scientists with experiences in VCA met in Banff and agreed on a standardized classification. Scores are mainly based on localization and intensity of infiltrates in the skin. Future additions to the current Banff score have been proposed and may include a graded assessment of clinical symptoms, supplemental immunohistological evaluations characterizing infiltrating cells (e.g., CD4<sup>+</sup>, CD8<sup>+</sup> T cell or B cell) and humoral rejections.[<xref ref-type="bibr" rid="CR43">43</xref>]</p><p>According to the Banff-07 classification, acute cellular mediated rejection is graded into 5 categories. Absent or rare infiltration define grade 0; grade I rejection is characterized by the appearance of mild perivascular infiltration. Advanced infiltrates with or without mild involvement of the epidermis, and/or adnexa defines grade II; while the addition of epithelial apoptosis, dyskeratosis, and/or keratinolysis defines grade III. Grade IV, finally, includes frank necrosis of epidermis, or other skin structures.[<xref ref-type="bibr" rid="CR43">43</xref>]</p><p>It has been suggested that the current Banff-07 classification for VCA may not be reflective of critical aspects of rejection. In a series of more than 100 biopsies of face transplant recipients, rejections have been linked to lymphocyte associated injuries in epidermal rete ridges, follicular infundibula and dermal microvessels. Of note, during active rejection, infiltrates consisted predominantly of lymphocytes of donor origin with an immunophenotype typical of resident memory T-cell subsets. These results may not only provide additional information for a more concise grading system, but may also provide novel biological insights into the mechanisms of VCAs.[<xref ref-type="bibr" rid="CR49">49</xref>]</p></sec><sec id="Sec6"><title>Antibody-mediated rejection (AMR)</title><p>A complex medical history including trauma and blood transfusions with subsequent sensitization is probable in patients qualifying for VCAs. In renal transplantation, patients have been transplanted against positive complement-dependent cytotoxicity (CDC) cross-matches with extensive pre- and post-transplant immunosuppression.[<xref ref-type="bibr" rid="CR50">50</xref>] Whether similar approaches may also apply in VCA is largely unknown. VCAs have usually been followed closely for donor-recipient crossmatches comparable to the approach in SOT. Thus far, there have been only very few reports of either AMR in VCA,[<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref>] circulating donor-specific antibodies (DSAs), or the deposition of the complement product C4d in VCA recipients.[<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref>] Of note, AMR is currently not part of the Banff-07 VCA classification system.</p><p>Pretransplant panel reactive antibody (PRA) scores are usually used to test the degree of sensitization in solid organ and VCA recipients alike. The score provides a relative estimate with a 100% PRA predicting a positive crossmatch against any given donor. We have recently successfully treated a highly-sensitized patient who developed a fulminant AMR. This patient was treated with an intensified immunosuppression consisting of plasmapheresis, eculizumab, bortezomib and campath-1H.[<xref ref-type="bibr" rid="CR54">54</xref>]</p><p>DSAs occurring late after hand transplantation have been reported recently. Rituximab (i.e., anti-CD20 antibody) normalized not only clinical symptoms, but also histological findings and DSA levels.[<xref ref-type="bibr" rid="CR55">55</xref>] Another hand transplantation patient presented with an aggressive thickening of arterial walls, detected by ultrasound biomicroscopy, an advanced imaging technique capable of revealing arterial thickening noninvasively. Further tests correlated findings with the deposition of the complement product C4d. Plasmapheresis, i.v. immunoglobulin, and a switch from MMF to sirolimus inhibited further progression of the lesions.[<xref ref-type="bibr" rid="CR56">56</xref>] Clearly, humoral immune responses are expected to gain further interest and relevance in VCA.</p></sec><sec id="Sec7"><title>Chronic graft deterioration in VCA</title><p>Although the skin is under constant surveillance, different properties of VCAs including muscle, bone, vessels, nerves, and other tissues may undergo immunologic and degenerative processes in the absence of direct visibility. The concept of &#x02018;split rejection&#x02019;, a process in which specific tissues undergo deterioration or immune attacks at a different tempo or intensity may also be of relevance impacting chronic graft deterioration in VCA.[<xref ref-type="bibr" rid="CR57">57</xref>] As in SOT, mechanisms of chronic graft deterioration are also not well-defined in VCA. Histological and clinical findings including vascular narrowing, loss of adnexa, skin and muscle atrophy, fibrosis of deep tissue, myointimal proliferation, and nail changes indicate chronic rejection in VCA.[<xref ref-type="bibr" rid="CR43">43</xref>]</p><p>Although confirmed, acute rejection episodes are frequent in VCA, and the field is looking back to a reasonable clinical experience, reports of chronic graft deterioration in VCA remain rare. At the same time, clinical evidence of chronic rejection exists: For example, a hand transplant recipient presented with arterial narrowing while superficial biopsies remained normal. DSAs were absent at the same time. Vasculopathy progressed, requiring subsequent amputation due to ischemia. Histological examination demonstrated predominantly vascular pathologies with hyperplasia of the intima in all donor arteries and involvement of the venous tissue as well. Of note, skin biopsies were scored grade 0-I.[<xref ref-type="bibr" rid="CR56">56</xref>] Other patients with clinical symptoms resembling chronic changes including atrophic skin and thinning of nails, pain, cold intolerance and compromised functionality have been reported. Clinical symptoms correlated with arterial narrowing and occlusion in addition to loss of adnexa, epidermal hyperkeratosis and perivascular inflammation.[<xref ref-type="bibr" rid="CR58">58</xref>]</p><p>Mechanisms of chronic graft deterioration remain obscure both in VCA and SOT. Hind-limb allografts in rats developed chronic changes following multiple acute rejection episodes, which were treated suboptimally. Myointimal proliferation, causing subtotal arterial occlusion was observed by day 90, while muscular atrophy and fibrosis became evident by day 60. While fibrosis has thus far been mainly linked to ischemia subsequent to advanced vasculopathy, profibrotic gene expression implicated additional causes, such as infiltrating macrophages and direct injury to muscle cells as aspects of chronic changes. Other interesting aspects include findings of mild vasculitis; while skin, muscle, and bone were unaffected, providing further evidence of the relevance of split rejection in VCA.[<xref ref-type="bibr" rid="CR59">59</xref>]</p></sec><sec id="Sec8"><title>Clinical and experimental tolerance approaches in VCA</title><p>Tolerance protocols have been attempted in both experimental and clinical settings. The first human face transplant recipient received 2 injections of donor BM cells in consistency with the Miami protocol, however, long-term microchimerism could not be documented and triple immunosuppressive therapy plus additional immunomodulatory treatment were necessary to control rejection episodes.[<xref ref-type="bibr" rid="CR37">37</xref>] The Pittsburgh protocol, applied in 5 hand transplantation patients, was able to keep patients on a maintenance tacrolimus monotherapy, although controls have been missing. This protocol consists of a lymphocyte-depleting induction therapy with alemtuzumab in combination with methylprednisone and a single, unmodified, donor BM cell infusion on day 14 after transplantation. DSA and C4d deposits detected in parallel to acute T cell rejections responded to topical treatment or methylprednisone infusions. Deep biopsies by 1 and 2 years revealed only focal muscle atrophy. Evaluations by high-resolution ultrasound biomicroscopy demonstrated minor to moderate vascular irregularities in 2 cases with some narrowing of luminal diameter and increased intimal-media thickness, respectively.[<xref ref-type="bibr" rid="CR40">40</xref>] Of note, peripheral chimerism was not detected in any of the VCA patients receiving the Pittsburgh protocol.</p><p>Stable mixed chimerism, in contrast, was achieved in VCA transplants across major histocompatibility complex (MHC) barriers in large animal models. In a pig model, a non-myeloablative conditioning regimen with T cell depletion by CD3-immunotoxin, total body irradiation, and donor-specific hematopoietic stem cell transfusion (HCT) was followed by a 45 day course of CsA. VCA transplants consisting of a vascularized full thickness skin flap were performed at varying intervals after HCT. Rejections were absent during an observation period up to 500 days. Of note, 2 animals with very high chimerism levels developed graft versus host disease (GvHD). Nevertheless, GvHD could be contained with an immunosuppression consisting of CsA and steroids.[<xref ref-type="bibr" rid="CR60">60</xref>] Achieving tolerance or the minimization of immunosuppression will be critical in improving the clinical applicability of VCAs, and future research will certainly focus on this area.</p></sec><sec id="Sec9"><title>Ischemia/reperfusion injury (IRI)</title><p>Both ischemia and reperfusion set mechanisms in place that initiate innate and adaptive immune responses contributing to acute rejection and chronic graft deterioration.[<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref>] In the presence of inadequate blood supply and oxygen deprivation, imbalances of cellular ion homeostasis and an augmented permeability of cell membranes occur simultaneously.[<xref ref-type="bibr" rid="CR63">63</xref>] Anaerobic metabolism and a buildup of lactate results in accumulation of proinflammatory mediators.[<xref ref-type="bibr" rid="CR64">64</xref>] Of note, restored blood flow does not restore function immediately, but leads to additional damages recognized as reperfusion injury. During IRI endothelial, parenchymal and immune cells become activated and reactive oxygen species, inflammatory cytokines, and complement products contribute to a furthermore augmented injury. Additional consequences include an impaired microvascular perfusion with secondary ischemia in the transplanted organ and the promotion of a &#x02018;cytokine storm&#x02019; that may finally lead to the development of systemic inflammatory response syndrome (SIRS).[<xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR65">65</xref>] Consequences of IRI have been extensively analyzed in SOT. IRI has only recently received attention in VCA where injury patterns of skeletal and cardial muscle demonstrated parallels.[<xref ref-type="bibr" rid="CR64">64</xref>] As VCA is composed of different tissues, consequences of IRI may differ in a tissue-specific manner. Muscle and adipose tissue have an enhanced metabolism and are therefore more susceptible to damage.[<xref ref-type="bibr" rid="CR66">66</xref>] Of note, viable skin could still be found in musculocutaneous autografts, although muscular tissue had already demonstrated necrotic changes.[<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>]</p><p>Time of tolerable ischemia, although of utmost clinical relevance, has thus far not been defined. In rat experiments, ischemic times exceeding 12 h drastically reduced the survival of musculocutaneous flaps. A histological analysis of biopsies in flaps with brief or prolonged ischemia (24 h) revealed no difference in the early onset of acute rejections, but demonstrated an accelerated inflammation in grafts with a prolonged ischemia.[<xref ref-type="bibr" rid="CR69">69</xref>] Other experiments have also shown that prolonged ischemia in models of VCA-augmented adaptive immunity and increased rates of acute rejections.[<xref ref-type="bibr" rid="CR70">70</xref>] Tolerable clinical ischemic times are currently not defined and clinical practice has aimed for brief periods of ischemia.[<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref>] Exploring mechanisms of IRI in VCA will be critical as tolerable prolonged ischemia will increase the availability of donors. To this end, novel preservation, developed in SOT are noteworthy.[<xref ref-type="bibr" rid="CR73">73</xref>] Pulsatile perfusion has been successfully used clinically in SOT and linked to endothelial and epithelial protection.[<xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref>] Future studies in VCA will need to explore if similar concepts and mechanisms may also be of relevance and benefit in VCAs.</p></sec></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusions</title><p>VCA has become a clinical reality during the last decade. Face and hand transplants have been successfully performed with excellent functional and esthetic outcomes by several centers in the world, and some patients have achieved a minimization of immunosuppression. While progress has been enormous, several open questions in regard to mechanisms of rejections, tolerance or minimization of immunosuppression, and the effects of unspecific injuries, consequences of IRI remain. Although critical aspects of the success of VCA are based on the experience in SOT, VCA-specific aspects need to be recognized and addressed. Most importantly, VCA is as much as SOT, a field which will thrive in a multidisciplinary approach synergizing the clinical and research expertise in tackling many unresolved issues in the field.</p></sec></body><back><fn-group><fn><p>
<bold>How to cite this article</bold>: Edtinger K, Yang X, Uehara H, Tullius SG. Current status of vascularized composite tissue allotransplantation. Burn Trauma 2014;2:53&#x02013;60.</p><p>
<bold>Source of Support</bold>: Supported by grants from the NIH (RO1AG039449) and the Carlos Slim Foundation de la Salud (all to SGT), and KE was supported by DFG grant KFO 243/1. <bold>Conflict of Interest</bold>: None declared.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starzl</surname><given-names>R</given-names></name><name><surname>Brandacher</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Carbonell</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Schnider</surname><given-names>J</given-names></name><etal/></person-group><article-title>Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation</article-title><source>Clin Dev Immunol</source><year>2013</year><volume>2013</volume><fpage>402980</fpage><pub-id pub-id-type="doi">10.1155/2013/402980</pub-id><pub-id pub-id-type="pmid">23431325</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>JH</given-names></name><name><surname>Merrill</surname><given-names>JP</given-names></name><name><surname>Murray</surname><given-names>JE</given-names></name></person-group><article-title>Renal homotransplantation in identical twins</article-title><source>Surg Forum</source><year>1956</year><volume>6</volume><fpage>432</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">13391513</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>JP</given-names></name><name><surname>Murray</surname><given-names>JE</given-names></name><name><surname>Harrison</surname><given-names>JH</given-names></name><name><surname>Friedman</surname><given-names>EA</given-names></name><name><surname>Dealy</surname><given-names>JB</given-names><suffix>Jr</suffix></name><name><surname>Dammin</surname><given-names>GJ</given-names></name></person-group><article-title>Successful homotransplantation of the kidney between nonidentical twins</article-title><source>N Engl J Med</source><year>1960</year><volume>262</volume><fpage>1251</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1056/NEJM196006232622501</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>JE</given-names></name><name><surname>Merrill</surname><given-names>JP</given-names></name><name><surname>Harrison</surname><given-names>JH</given-names></name><name><surname>Wilson</surname><given-names>RE</given-names></name><name><surname>Dammin</surname><given-names>GJ</given-names></name></person-group><article-title>Prolonged survival of human-kidney homografts by immunosuppressive drug therapy</article-title><source>N Engl J Med</source><year>1963</year><volume>268</volume><fpage>1315</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1056/NEJM196306132682401</pub-id><pub-id pub-id-type="pmid">13936775</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>GR</given-names></name><name><surname>Breidenbach</surname><given-names>WC</given-names><suffix>3rd</suffix></name><name><surname>Ildstad</surname><given-names>ST</given-names></name><name><surname>Marvin</surname><given-names>MM</given-names></name><name><surname>Buell</surname><given-names>JF</given-names></name><name><surname>Ravindra</surname><given-names>KV</given-names></name></person-group><article-title>The history of human composite tissue allotransplantation</article-title><source>Transplant Proc</source><year>2009</year><volume>41</volume><fpage>466</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2009.01.026</pub-id><pub-id pub-id-type="pmid">19328905</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Robert G. Hand transplanted from cadaver is reamputated. Med Trib Med News 1964;5.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>JE</given-names></name></person-group><article-title>The first successful organ transplants in man</article-title><source>J Am Coll Surg</source><year>2005</year><volume>200</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2004.09.033</pub-id><pub-id pub-id-type="pmid">15631913</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borel</surname><given-names>JF</given-names></name><name><surname>Kis</surname><given-names>ZL</given-names></name></person-group><article-title>The discovery and development of cyclosporine (Sandimmune)</article-title><source>Transplant Proc</source><year>1991</year><volume>23</volume><fpage>1867</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2053181</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Kino</surname><given-names>T</given-names></name><name><surname>Hatanaka</surname><given-names>H</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Okuhara</surname><given-names>M</given-names></name><name><surname>Kohsaka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis</article-title><source>Transplant Proc</source><year>1987</year><volume>19</volume><fpage>4</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2445072</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Yaremchuk</surname><given-names>MJ</given-names></name><name><surname>Pan</surname><given-names>YC</given-names></name><name><surname>Randolph</surname><given-names>MA</given-names></name><name><surname>Tan</surname><given-names>CM</given-names></name><name><surname>Weiland</surname><given-names>AJ</given-names></name></person-group><article-title>Relative antigenicity of components of a vascularized limb allograft</article-title><source>Plast Reconstr Surg</source><year>1991</year><volume>87</volume><fpage>401</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1097/00006534-199103000-00001</pub-id><pub-id pub-id-type="pmid">1998012</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ust&#x000fc;ner</surname><given-names>ET</given-names></name><name><surname>Zdichavsky</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Edelstein</surname><given-names>J</given-names></name><name><surname>Maldonado</surname><given-names>C</given-names></name><name><surname>Ray</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy</article-title><source>Transplantation</source><year>1998</year><volume>66</volume><fpage>1581</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00007890-199810270-00107</pub-id><pub-id pub-id-type="pmid">9884243</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubernard</surname><given-names>JM</given-names></name><name><surname>Owen</surname><given-names>E</given-names></name><name><surname>Herzberg</surname><given-names>G</given-names></name><name><surname>Lanzetta</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>X</given-names></name><name><surname>Kapila</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human hand allograft: Report on first 6 months</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1315</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)02062-0</pub-id><pub-id pub-id-type="pmid">10218530</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strome</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Esclamado</surname><given-names>R</given-names></name><name><surname>Hicks</surname><given-names>D</given-names></name><name><surname>Lorenz</surname><given-names>RR</given-names></name><name><surname>Braun</surname><given-names>W</given-names></name><etal/></person-group><article-title>Laryngeal transplantation and 40-month follow-up</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>1676</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJM200105313442204</pub-id><pub-id pub-id-type="pmid">11386266</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>MH</given-names></name><name><surname>Brauns</surname><given-names>L</given-names></name><name><surname>Gonschorek</surname><given-names>O</given-names></name><name><surname>B&#x000fc;hren</surname><given-names>V</given-names></name><name><surname>Hofmann</surname><given-names>GO</given-names></name></person-group><article-title>Vascularised knee joint transplantation in man: The first two years experience</article-title><source>Eur J Surg</source><year>2000</year><volume>166</volume><fpage>320</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/110241500750009186</pub-id><pub-id pub-id-type="pmid">10817331</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavadas</surname><given-names>PC</given-names></name><name><surname>Thione</surname><given-names>A</given-names></name><name><surname>Carballeira</surname><given-names>A</given-names></name><name><surname>Blanes</surname><given-names>M</given-names></name></person-group><article-title>Bilateral transfemoral lower extremity transplantation: Result at 1 year</article-title><source>Am J Transplant</source><year>2013</year><volume>13</volume><fpage>1343</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/ajt.12178</pub-id><pub-id pub-id-type="pmid">23433015</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barret</surname><given-names>JP</given-names></name><name><surname>Gavald&#x000e0;</surname><given-names>J</given-names></name><name><surname>Bueno</surname><given-names>J</given-names></name><name><surname>Nuvials</surname><given-names>X</given-names></name><name><surname>Pont</surname><given-names>T</given-names></name><name><surname>Masnou</surname><given-names>N</given-names></name><etal/></person-group><article-title>Full face transplant: The first case report</article-title><source>Ann Surg</source><year>2011</year><volume>254</volume><fpage>252</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e318226a607</pub-id><pub-id pub-id-type="pmid">21772126</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devauchelle</surname><given-names>B</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Lengel&#x000e9;</surname><given-names>B</given-names></name><name><surname>Morelon</surname><given-names>E</given-names></name><name><surname>Testelin</surname><given-names>S</given-names></name><name><surname>Michallet</surname><given-names>M</given-names></name><etal/></person-group><article-title>First human face allograft: Early report</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>203</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68935-6</pub-id><pub-id pub-id-type="pmid">16844489</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>HQ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>XB</given-names></name><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>JS</given-names></name></person-group><article-title>Composite tissue allograft transplantation of cephalocervical skin flap and two ears</article-title><source>Plast Reconstr Surg</source><year>2005</year><volume>115</volume><fpage>31</fpage><lpage>5e</lpage><pub-id pub-id-type="doi">10.1097/01.PRS.0000153038.31865.02</pub-id><pub-id pub-id-type="pmid">15622228</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landin</surname><given-names>L</given-names></name><name><surname>Cavadas</surname><given-names>PC</given-names></name><name><surname>Nthumba</surname><given-names>P</given-names></name><name><surname>Ibanez</surname><given-names>J</given-names></name><name><surname>Vera-Sempere</surname><given-names>F</given-names></name></person-group><article-title>Preliminary results of bilateral arm transplantation</article-title><source>Transplantation</source><year>2009</year><volume>88</volume><fpage>749</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181b3921a</pub-id><pub-id pub-id-type="pmid">19741477</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>GO</given-names></name><name><surname>Kirschner</surname><given-names>MH</given-names></name></person-group><article-title>Clinical experience in allogeneic vascularized bone and joint allografting</article-title><source>Microsurgery</source><year>2000</year><volume>20</volume><fpage>375</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/1098-2752(2000)20:8&#x0003c;375::AID-MICR6&#x0003e;3.0.CO;2-0</pub-id><pub-id pub-id-type="pmid">11150987</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Akino</surname><given-names>T</given-names></name><name><surname>Shigetomi</surname><given-names>M</given-names></name><name><surname>Muramatsu</surname><given-names>K</given-names></name><name><surname>Kawai</surname><given-names>S</given-names></name></person-group><article-title>Vascularized bone allografts: Review of current concepts</article-title><source>Microsurgery</source><year>1994</year><volume>15</volume><fpage>831</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/micr.1920151203</pub-id><pub-id pub-id-type="pmid">7707923</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>GO</given-names></name><name><surname>Kirschner</surname><given-names>MH</given-names></name><name><surname>Buhren</surname><given-names>V</given-names></name><name><surname>Land</surname><given-names>W</given-names></name></person-group><article-title>Allogenic vascularized transplantation of a human femoral diaphysis under cyclosporin A immunosuppression</article-title><source>Transplant Int</source><year>1995</year><volume>8</volume><fpage>418</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1432-2277.1995.tb01548.x</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birchall</surname><given-names>M</given-names></name></person-group><article-title>Tongue transplantation</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1663</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16287-9</pub-id><pub-id pub-id-type="pmid">15158625</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tintinago</surname><given-names>LF</given-names></name><name><surname>Herrera</surname><given-names>DA</given-names></name><name><surname>Medina</surname><given-names>E</given-names></name><name><surname>Pati&#x000f1;o</surname><given-names>JH</given-names></name><name><surname>Cano</surname><given-names>F</given-names></name><name><surname>Restrepo</surname><given-names>CS</given-names></name></person-group><article-title>Ultrasonographic evaluation of a vascularized tracheal transplantation</article-title><source>J Ultrasound Med</source><year>2005</year><volume>24</volume><fpage>1145</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16040831</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>DM</given-names></name><name><surname>Tzakis</surname><given-names>AG</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Madariaga</surname><given-names>J</given-names></name><name><surname>Mittal</surname><given-names>NK</given-names></name><name><surname>Nery</surname><given-names>J</given-names></name><etal/></person-group><article-title>Transplantation of the abdominal wall</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>2173</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13769-5</pub-id><pub-id pub-id-type="pmid">12842369</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Nie</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A preliminary report of penile transplantation</article-title><source>Eur Urol</source><year>2006</year><volume>50</volume><fpage>851</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2006.07.026</pub-id><pub-id pub-id-type="pmid">16930814</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fageeh</surname><given-names>W</given-names></name><name><surname>Raffa</surname><given-names>H</given-names></name><name><surname>Jabbad</surname><given-names>H</given-names></name><name><surname>Marzouki</surname><given-names>A</given-names></name></person-group><article-title>Transplantation of the human uterus</article-title><source>Int J Gynaecol Obstet</source><year>2002</year><volume>76</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0020-7292(01)00597-5</pub-id><pub-id pub-id-type="pmid">11880127</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Health R. Services Administration, D.o.H. &#x00026; Human, S. Organ procurement and transplantation network</collab></person-group><article-title>Organ procurement and transplantation network. Final rule</article-title><source>Federal Register</source><year>2013</year><volume>78</volume><fpage>40033</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23833809</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantieri</surname><given-names>L</given-names></name><name><surname>Hivelin</surname><given-names>M</given-names></name><name><surname>Audard</surname><given-names>V</given-names></name><name><surname>Benjoar</surname><given-names>MD</given-names></name><name><surname>Meningaud</surname><given-names>JP</given-names></name><name><surname>Bellivier</surname><given-names>F</given-names></name><etal/></person-group><article-title>Feasibility, reproducibility, risks and benefits of face transplantation: A prospective study of outcomes</article-title><source>Am J Transplant</source><year>2011</year><volume>11</volume><fpage>367</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2010.03406.x</pub-id><pub-id pub-id-type="pmid">21272240</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Siso</surname><given-names>JR</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Bueno</surname><given-names>EM</given-names></name><name><surname>Sisk</surname><given-names>GC</given-names></name><name><surname>Pribaz</surname><given-names>JJ</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Facial allotransplantation: A 3-year follow-up report</article-title><source>J Plast Reconstr Aesthet Surg</source><year>2013</year><volume>66</volume><fpage>1458</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.bjps.2013.06.046</pub-id><pub-id pub-id-type="pmid">23911716</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human facial allotransplantation: A 2-year follow-up study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>631</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61276-3</pub-id><pub-id pub-id-type="pmid">18722867</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinojosa P&#x000e9;rez</surname><given-names>R</given-names></name><name><surname>Porras L&#x000f3;pez</surname><given-names>M</given-names></name><name><surname>Escoresca-Ortega</surname><given-names>AM</given-names></name><name><surname>Herruzo Avil&#x000e9;s</surname><given-names>A</given-names></name><name><surname>Le&#x000f3;n</surname><given-names>A</given-names></name><name><surname>Noval</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Severe rhabdomyolysis after allogeneic transplantation of facial structures: A case report</article-title><source>Transplant Proc</source><year>2010</year><volume>42</volume><fpage>3081</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2010.08.007</pub-id><pub-id pub-id-type="pmid">20970614</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomahac</surname><given-names>B</given-names></name><name><surname>Pribaz</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Annino</surname><given-names>D</given-names></name><name><surname>Caterson</surname><given-names>S</given-names></name><name><surname>Sampson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft</article-title><source>Am J Transplant</source><year>2011</year><volume>11</volume><fpage>386</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2010.03368.x</pub-id><pub-id pub-id-type="pmid">21214855</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siemionow</surname><given-names>M</given-names></name><name><surname>Papay</surname><given-names>F</given-names></name><name><surname>Alam</surname><given-names>D</given-names></name><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Djohan</surname><given-names>R</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Near-total human face transplantation for a severely disfigured patient in the USA</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>203</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61155-7</pub-id><pub-id pub-id-type="pmid">19608265</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantieri</surname><given-names>L</given-names></name><name><surname>Meningaud</surname><given-names>JP</given-names></name><name><surname>Grimbert</surname><given-names>P</given-names></name><name><surname>Bellivier</surname><given-names>F</given-names></name><name><surname>Lefaucheur</surname><given-names>JP</given-names></name><name><surname>Ortonne</surname><given-names>N</given-names></name><etal/></person-group><article-title>Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: A 1-year follow-up study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>639</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61277-5</pub-id><pub-id pub-id-type="pmid">18722868</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Siso</surname><given-names>JR</given-names></name><name><surname>Bueno</surname><given-names>EM</given-names></name><name><surname>Sisk</surname><given-names>GC</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Pomahac</surname><given-names>B</given-names></name><name><surname>Tullius</surname><given-names>SG</given-names></name></person-group><article-title>Vascularized composite tissue allotransplantation-state of the art</article-title><source>Clin Transplant</source><year>2013</year><volume>27</volume><fpage>330</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/ctr.12117</pub-id><pub-id pub-id-type="pmid">23581799</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubernard</surname><given-names>JM</given-names></name><name><surname>Lengel&#x000e9;</surname><given-names>B</given-names></name><name><surname>Morelon</surname><given-names>E</given-names></name><name><surname>Testelin</surname><given-names>S</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Moure</surname><given-names>C</given-names></name><etal/></person-group><article-title>Outcomes 18 months after the first human partial face transplantation</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2451</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa072828</pub-id><pub-id pub-id-type="pmid">18077810</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavadas</surname><given-names>PC</given-names></name><name><surname>Ibanez</surname><given-names>J</given-names></name><name><surname>Thione</surname><given-names>A</given-names></name></person-group><article-title>Surgical aspects of a lower face, mandible, and tongue allotransplantation</article-title><source>J Reconstr Microsurg</source><year>2012</year><volume>28</volume><fpage>43</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1284236</pub-id><pub-id pub-id-type="pmid">21780015</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petruzzo</surname><given-names>P</given-names></name><name><surname>Kanitakis</surname><given-names>J</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Pialat</surname><given-names>JB</given-names></name><name><surname>Boutroy</surname><given-names>S</given-names></name><name><surname>Charpulat</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term follow-up in composite tissue allotransplantation: In-depth study of five (hand and face) recipients</article-title><source>Am J Transplant</source><year>2011</year><volume>11</volume><fpage>808</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03469.x</pub-id><pub-id pub-id-type="pmid">21446980</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneeberger</surname><given-names>S</given-names></name><name><surname>Gorantla</surname><given-names>VS</given-names></name><name><surname>Brandacher</surname><given-names>G</given-names></name><name><surname>Zeevi</surname><given-names>A</given-names></name><name><surname>Demetris</surname><given-names>AJ</given-names></name><name><surname>Lunz</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression</article-title><source>Ann Surg</source><year>2013</year><volume>257</volume><fpage>345</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e31826d90bb</pub-id><pub-id pub-id-type="pmid">23001085</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breidenbach</surname><given-names>WC</given-names></name><name><surname>Gonzales</surname><given-names>NR</given-names></name><name><surname>Kaufman</surname><given-names>CL</given-names></name><name><surname>Klapheke</surname><given-names>M</given-names></name><name><surname>Tobin</surname><given-names>GR</given-names></name><name><surname>Gorantla</surname><given-names>VS</given-names></name></person-group><article-title>Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant</article-title><source>J Hand Surg Am</source><year>2008</year><volume>33</volume><fpage>1039</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jhsa.2008.02.015</pub-id><pub-id pub-id-type="pmid">18762094</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneeberger</surname><given-names>S</given-names></name><name><surname>Gorantla</surname><given-names>VS</given-names></name><name><surname>van Riet</surname><given-names>RP</given-names></name><name><surname>Lanzetta</surname><given-names>M</given-names></name><name><surname>Vereecken</surname><given-names>P</given-names></name><name><surname>van Holder</surname><given-names>C</given-names></name><etal/></person-group><article-title>Atypical acute rejection after hand transplantation</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>688</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2007.02105.x</pub-id><pub-id pub-id-type="pmid">18261182</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cendales</surname><given-names>LC</given-names></name><name><surname>Kanitakis</surname><given-names>J</given-names></name><name><surname>Schneeberger</surname><given-names>S</given-names></name><name><surname>Burns</surname><given-names>C</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><name><surname>Landin</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Banff 2007 working classification of skin-containing composite tissue allograft pathology</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>1396</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02243.x</pub-id><pub-id pub-id-type="pmid">18444912</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hautz</surname><given-names>T</given-names></name><name><surname>Zelger</surname><given-names>BG</given-names></name><name><surname>Weissenbacher</surname><given-names>A</given-names></name><name><surname>Zelger</surname><given-names>B</given-names></name><name><surname>Brandacher</surname><given-names>G</given-names></name><name><surname>Landin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Standardizing skin biopsy sampling to assess rejection in vascularized composite allotransplantation</article-title><source>Clin Transplant</source><year>2013</year><volume>27</volume><fpage>E81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/ctr.12086</pub-id><pub-id pub-id-type="pmid">23452279</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejarano</surname><given-names>PA</given-names></name><name><surname>Levi</surname><given-names>D</given-names></name><name><surname>Nassiri</surname><given-names>M</given-names></name><name><surname>Vincek</surname><given-names>V</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Weppler</surname><given-names>D</given-names></name><etal/></person-group><article-title>The Pathology of full-thickness cadaver skin transplant for large abdominal defects: A proposed grading system for skin allograft acute rejection</article-title><source>Am J Surg Pathol</source><year>2004</year><volume>28</volume><fpage>670</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/00000478-200405000-00016</pub-id><pub-id pub-id-type="pmid">15105657</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanitakis</surname><given-names>J</given-names></name><name><surname>Petruzzo</surname><given-names>P</given-names></name><name><surname>Jullien</surname><given-names>D</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Dezza</surname><given-names>MC</given-names></name><name><surname>Claudy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pathological score for the evaluation of allograft rejection in human hand (composite tissue) allotransplantation</article-title><source>Eur J Dermatol</source><year>2005</year><volume>15</volume><fpage>235</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16048749</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneeberger</surname><given-names>S</given-names></name><name><surname>Kreczy</surname><given-names>A</given-names></name><name><surname>Brandacher</surname><given-names>G</given-names></name><name><surname>Steurer</surname><given-names>W</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name></person-group><article-title>Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><fpage>1372</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2004.00518.x</pub-id><pub-id pub-id-type="pmid">15268743</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cendales</surname><given-names>LC</given-names></name><name><surname>Kirk</surname><given-names>AD</given-names></name><name><surname>Moresi</surname><given-names>JM</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><name><surname>Kleiner</surname><given-names>DE</given-names></name></person-group><article-title>Composite tissue allotransplantation: Classification of clinical acute skin rejection</article-title><source>Transplantation</source><year>2006</year><volume>81</volume><fpage>418</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000185304.49987.d8</pub-id><pub-id pub-id-type="pmid">16477229</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Lian CG, Bueno EM, Granter SR, Laga AC, Saavedra AP, Lin WM, <italic>et al.</italic> Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol 2014.</mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>HS</given-names></name><name><surname>Jackson</surname><given-names>AM</given-names></name><name><surname>Zachary</surname><given-names>AA</given-names></name><name><surname>Montgomery</surname><given-names>RA</given-names></name></person-group><article-title>Transplanting the highly sensitized patient: Trials and tribulations</article-title><source>Curr Opin Nephrol Hypertens</source><year>2013</year><volume>22</volume><fpage>681</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/MNH.0b013e328365b3b9</pub-id><pub-id pub-id-type="pmid">24076558</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petruzzo</surname><given-names>P</given-names></name><name><surname>Lanzetta</surname><given-names>M</given-names></name><name><surname>Dubernard</surname><given-names>JM</given-names></name><name><surname>Landin</surname><given-names>L</given-names></name><name><surname>Cavadas</surname><given-names>P</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name><etal/></person-group><article-title>The international registry on hand and composite tissue transplantation</article-title><source>Transplantation</source><year>2010</year><volume>90</volume><fpage>1590</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181ff1472</pub-id><pub-id pub-id-type="pmid">21052038</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanitakis</surname><given-names>J</given-names></name><name><surname>McGregor</surname><given-names>B</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Petruzzo</surname><given-names>P</given-names></name><name><surname>Morelon</surname><given-names>E</given-names></name><name><surname>Devauchelle</surname><given-names>B</given-names></name><etal/></person-group><article-title>Absence of c4d deposition in human composite tissue (hands and face) allograft biopsies: An immunoperoxidase study</article-title><source>Transplantation</source><year>2007</year><volume>84</volume><fpage>265</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000266899.93315.52</pub-id><pub-id pub-id-type="pmid">17667820</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelon</surname><given-names>E</given-names></name><name><surname>Kanitakis</surname><given-names>J</given-names></name><name><surname>Petruzzo</surname><given-names>P</given-names></name></person-group><article-title>Immunological issues in clinical composite tissue allotransplantation: Where do we stand today?</article-title><source>Transplantation</source><year>2012</year><volume>93</volume><fpage>855</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e31824728b8</pub-id><pub-id pub-id-type="pmid">22538449</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Chandraker A, Arscott R, Murphy GF, Lian CG, Bueno EM, Marty FM, <italic>et al.</italic> The management of antibody-mediated rejection in the first pre-sensitized recipient of a full-face allotransplant. Am J Transplant 2014.</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissenbacher</surname><given-names>A</given-names></name><name><surname>Hautz</surname><given-names>T</given-names></name><name><surname>Zelger</surname><given-names>B</given-names></name><name><surname>Zelger</surname><given-names>BG</given-names></name><name><surname>Mayr</surname><given-names>V</given-names></name><name><surname>Brandacher</surname><given-names>G</given-names></name><etal/></person-group><article-title>Antibody-mediated rejection in hand transplantation</article-title><source>Transpl Int</source><year>2014</year><volume>27</volume><fpage>e13</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/tri.12233</pub-id><pub-id pub-id-type="pmid">24266875</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>CL</given-names></name><name><surname>Ouseph</surname><given-names>R</given-names></name><name><surname>Blair</surname><given-names>B</given-names></name><name><surname>Kutz</surname><given-names>JE</given-names></name><name><surname>Tsai</surname><given-names>TM</given-names></name><name><surname>Scheker</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Graft vasculopathy in clinical hand transplantation</article-title><source>Am J Transplant</source><year>2012</year><volume>12</volume><fpage>1004</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03915.x</pub-id><pub-id pub-id-type="pmid">22325051</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>I</given-names></name><name><surname>Pomahac</surname><given-names>B</given-names></name></person-group><article-title>Split rejection in vascularized composite allotransplantation</article-title><source>Eplasty</source><year>2013</year><volume>13</volume><fpage>e53</fpage><pub-id pub-id-type="pmid">24244785</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>G</given-names></name><name><surname>Xiang</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><etal/></person-group><article-title>A report of 15 hand allotransplantations in 12 patients and their outcomes in China</article-title><source>Transplantation</source><year>2012</year><volume>94</volume><fpage>1052</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e31826c3915</pub-id><pub-id pub-id-type="pmid">23169225</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unadkat</surname><given-names>JV</given-names></name><name><surname>Schneeberger</surname><given-names>S</given-names></name><name><surname>Horibe</surname><given-names>EH</given-names></name><name><surname>Goldbach</surname><given-names>C</given-names></name><name><surname>Solari</surname><given-names>MG</given-names></name><name><surname>Washington</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation</article-title><source>Am J Transplant</source><year>2010</year><volume>10</volume><fpage>251</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02941.x</pub-id><pub-id pub-id-type="pmid">20041866</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>DA</given-names></name><name><surname>Kurtz</surname><given-names>JM</given-names></name><name><surname>Mallard</surname><given-names>C</given-names></name><name><surname>Albritton</surname><given-names>A</given-names></name><name><surname>Duran-Struuck</surname><given-names>R</given-names></name><name><surname>Farkash</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Vascularized composite allograft tolerance across MHC barriers in a large animal model</article-title><source>Am J Transplant</source><year>2014</year><volume>14</volume><fpage>343</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/ajt.12560</pub-id><pub-id pub-id-type="pmid">24405666</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuuminen</surname><given-names>R</given-names></name><name><surname>Syrj&#x000e4;l&#x000e4;</surname><given-names>S</given-names></name><name><surname>Krebs</surname><given-names>R</given-names></name><name><surname>Ker&#x000e4;nen</surname><given-names>MA</given-names></name><name><surname>Koli</surname><given-names>K</given-names></name><name><surname>Abo-Ramadan</surname><given-names>U</given-names></name><etal/></person-group><article-title>Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>1138</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.005249</pub-id><pub-id pub-id-type="pmid">21844074</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>RJ</given-names></name><name><surname>Dikman</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Martinelli</surname><given-names>GP</given-names></name></person-group><article-title>Cold ischemic injury accelerates the progression to chronic rejection in a rat cardiac allograft model</article-title><source>Transplantation</source><year>1997</year><volume>64</volume><fpage>1102</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00007890-199710270-00003</pub-id><pub-id pub-id-type="pmid">9355823</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>H</given-names></name><name><surname>Rauen</surname><given-names>U</given-names></name></person-group><article-title>Ischemia-reperfusion injury: Processes in pathogenetic networks: A review</article-title><source>Transplant Proc</source><year>2007</year><volume>39</volume><fpage>481</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2006.12.012</pub-id><pub-id pub-id-type="pmid">17362763</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siemionow</surname><given-names>M</given-names></name><name><surname>Arslan</surname><given-names>E</given-names></name></person-group><article-title>Ischemia/reperfusion injury: A review in relation to free tissue transfers</article-title><source>Microsurgery</source><year>2004</year><volume>24</volume><fpage>468</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/micr.20060</pub-id><pub-id pub-id-type="pmid">15378577</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemasters</surname><given-names>JJ</given-names></name><name><surname>Thurman</surname><given-names>RG</given-names></name></person-group><article-title>Reperfusion injury after liver preservation for transplantation</article-title><source>Ann Rev Pharmacol Toxicol</source><year>1997</year><volume>37</volume><fpage>327</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.37.1.327</pub-id><pub-id pub-id-type="pmid">9131256</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaisdell</surname><given-names>FW</given-names></name></person-group><article-title>The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: A review</article-title><source>Cardiovasc Surg</source><year>2002</year><volume>10</volume><fpage>620</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0967-2109(02)00070-4</pub-id><pub-id pub-id-type="pmid">12453699</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>SF</given-names></name><name><surname>Pang</surname><given-names>CY</given-names></name><name><surname>Zhong</surname><given-names>A</given-names></name><name><surname>Boyd</surname><given-names>B</given-names></name><name><surname>Forrest</surname><given-names>CR</given-names></name></person-group><article-title>Assessment of ischemia-induced reperfusion injury in the pig latissimus dorsi myocutaneous flap model</article-title><source>Plast Reconstr Surg</source><year>1993</year><volume>92</volume><fpage>1162</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1097/00006534-199311000-00026</pub-id><pub-id pub-id-type="pmid">8234514</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenker</surname><given-names>JD</given-names></name><name><surname>Reus</surname><given-names>WF</given-names></name></person-group><article-title>Blood flow after warm ischemia in island flaps: Latissimus dorsi myocutaneous and epigastric flaps in the dog</article-title><source>Ann Plast Surg</source><year>1983</year><volume>10</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/00000637-198301000-00008</pub-id><pub-id pub-id-type="pmid">6830121</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name></person-group><article-title>Prolonged cold ischemic time results in increased acute rejection in a rat allotransplantation model</article-title><source>J Surg Res</source><year>2010</year><volume>164</volume><fpage>e299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2010.08.012</pub-id><pub-id pub-id-type="pmid">20934711</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradka</surname><given-names>SP</given-names></name><name><surname>Ong</surname><given-names>YS</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>SJ</given-names></name><name><surname>Baccarani</surname><given-names>A</given-names></name><name><surname>Messmer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Increased signs of acute rejection with ischemic time in a rat musculocutaneous allotransplant model</article-title><source>Transplant Proc</source><year>2009</year><volume>41</volume><fpage>531</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2009.01.021</pub-id><pub-id pub-id-type="pmid">19328919</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caterson</surname><given-names>EJ</given-names></name><name><surname>Lopez</surname><given-names>J</given-names></name><name><surname>Medina</surname><given-names>M</given-names></name><name><surname>Pomahac</surname><given-names>B</given-names></name><name><surname>Tullius</surname><given-names>SG</given-names></name></person-group><article-title>Ischemia-reperfusion injury in vascularized composite allotransplantation</article-title><source>J Craniofac Surg</source><year>2013</year><volume>24</volume><fpage>51</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/SCS.0b013e31827104e1</pub-id><pub-id pub-id-type="pmid">23321872</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomahac</surname><given-names>B</given-names></name><name><surname>Pribaz</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Bueno</surname><given-names>EM</given-names></name><name><surname>Diaz-Siso</surname><given-names>JR</given-names></name><name><surname>Rybicki</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Three patients with full facial transplantation</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>715</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1111432</pub-id><pub-id pub-id-type="pmid">22204672</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timsit</surname><given-names>MO</given-names></name><name><surname>Tullius</surname><given-names>SG</given-names></name></person-group><article-title>Hypothermic kidney preservation: A remembrance of the past in the future?</article-title><source>Curr Opin Organ Transplant</source><year>2011</year><volume>16</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/MOT.0b013e3283446b07</pub-id><pub-id pub-id-type="pmid">21415818</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moers</surname><given-names>C</given-names></name><name><surname>Smits</surname><given-names>JM</given-names></name><name><surname>Maathuis</surname><given-names>MH</given-names></name><name><surname>Treckmann</surname><given-names>J</given-names></name><name><surname>van Gelder</surname><given-names>F</given-names></name><name><surname>Napieralski</surname><given-names>BP</given-names></name><etal/></person-group><article-title>Machine perfusion or cold storage in deceased-donor kidney transplantation</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802289</pub-id><pub-id pub-id-type="pmid">19118301</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timsit</surname><given-names>MO</given-names></name><name><surname>Adams</surname><given-names>WJ</given-names></name><name><surname>Laguna-Fernandez</surname><given-names>A</given-names></name><name><surname>Ichimura</surname><given-names>T</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name><name><surname>Garc&#x000ed;a-Carde&#x000f1;a</surname><given-names>G</given-names></name><etal/></person-group><article-title>Flow is critical for maintaining a protective phenotype in renal proximal tubular cells</article-title><source>Am J Transplant</source><year>2013</year><volume>13</volume><fpage>1617</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/ajt.12242</pub-id><pub-id pub-id-type="pmid">23617882</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracia-Sancho</surname><given-names>J</given-names></name><name><surname>Villarreal</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tullius</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Flow cessation triggers endothelial dysfunction during organ cold storage conditions: Strategies for pharmacologic intervention</article-title><source>Transplantation</source><year>2010</year><volume>90</volume><fpage>142</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181e228db</pub-id><pub-id pub-id-type="pmid">20606606</pub-id></element-citation></ref></ref-list></back></article>